PHAT

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Headquartered in Florham Park, New Jersey, the company operates as a clinical-stage and commercial organization dedicated to addressing significant unmet medical needs in gastroenterology. Phathom's lead product is VOQUEZNA (vonoprazan), a potassium-competitive acid blocker approved by the FDA for treating erosive esophagitis and relieving heartburn associated with gastroesophageal reflux disease (GERD). The company acquired U.S. rights to vonoprazan through an exclusive license agreement with Takeda Pharmaceutical Company. VOQUEZNA represents the first new class of acid suppressants in decades and offers a differentiation from traditional proton pump inhibitors. Phathom commercially launched VOQUEZNA in the United States in 2022 and has been expanding its market presence through targeted physician engagement and patient access programs. The company also markets VOQUEZNA TRIPLE PAK, a co-packaged treatment for Helicobacter pylori infection. With approximately 200 employees, Phathom maintains a specialized commercial infrastructure focused on gastroenterologists and primary care physicians. The company continues to explore additional indications and formulations for vonoprazan while building its commercial capabilities in the competitive gastrointestinal pharmaceutical market.